Alteogen (196170 KS): Distinct Platform Technology; Biosimilar Pipeline; Potential Value Unlocking
Alteogen’s formulation platform change technology is in constant demand. The company can be potential first-mover in Eylea biosimilar. Its...
574 Views
Santen Pharmaceutical (4536 JP): Future Is Uncertain Beyond Eylea
Santen’s key drug to face biosimilar competition is the major overhang on the company’s near-term growth potential. The company does not have any...
425 Views
U.S. Equity Strategy: Several Indicators Suggest a Pullback Likely
Despite the bulls still being in control, we have several ongoing concerns and we cannot rule out the potential for a pullback. Below we highlight...
545 Views
U.S. Equities: Test Of The Lows Coming?
Now that the initial/primary low has been established and with the S&P 500 roughly 20% off the lows, we believe it is time to map out potential...
482 Views
Mylan N.V. (MYL US): Another Contrarian Pharmaceutical Investment
Mylan Nv (MYL US)Â stock has seen some downward pressure since 2015 after the increased capital expenditure and debt load for acquisitions...
558 Views